NovoCure News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

11.01.16	Novocure Announces Preliminary 2015 Operating Statistics (Businesswire)
07.01.16	Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients (Businesswire)
06.01.16	Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System (Businesswire)
04.01.16	Novocure to Participate in 34th Annual J.P. Morgan Healthcare Conference (Businesswire)
15.12.15	Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data (Businesswire)
15.12.15	Journal of the American Medical Association (JAMA) veröffentlicht Daten aus zulassungsrelevanter Phase-3-Studie zu Optune plus Temozolomid bei der Behandlung von neu diagnostiziertem Glioblastom (Businesswire)
15.12.15	Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma (Businesswire)
14.12.15	New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports (Businesswire)
03.12.15	Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts (Businesswire)
03.12.15	Vorläufige Daten aus Phase-2-Studie belegen Sicherheit der TTFields-Therapie bei Patienten mit Hirnmetastasen, bedingt durch nicht-kleinzelliges Lungenkarzinom (Businesswire)
02.12.15	Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer (Businesswire)
20.11.15	New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence (Businesswire)
19.11.15	Novocure kündigt 18 Präsentationen zur TTFields-Therapie auf dem SNO-Kongress 2015 an, darunter neue Analysen von Daten der EF-14 Studie bei neu diagnostiziertem Glioblastom (Businesswire)
17.11.15	Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015 (Businesswire)
17.11.15	Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data (Businesswire)
26.10.15	Novocure Reports Third Quarter 2015 Operating and Financial Results (Businesswire)
19.10.15	NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option (Businesswire)
16.10.15	Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015 (Businesswire)
16.10.15	Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26 (Businesswire)
07.10.15	NovoCure Limited Announces Closing of Initial Public Offering (Businesswire)
06.10.15	FDA erteilt Zulassung für Optune in Kombination mit Temozolomid für die Behandlung von neu diagnostizierten Glioblastomen (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	121.15	2.19 %	K V
Swiss Re	129.75	1.13 %	K V
Lonza Grp	526.00	0.88 %	K V
Logitech Intl	71.32	0.42 %	K V
UBS Group	28.36	0.21 %	K V
Alcon	76.16	-0.68 %	K V
Swiss Life Hldg	727.60	-0.82 %	K V
Givaudan	3’891.00	-1.07 %	K V
Novartis	92.50	-1.26 %	K V
Sonova Hldg	306.20	-1.89 %	K V